Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ibalizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Theratechnologies
Deal Size : Undisclosed
Deal Type : Acquisition
Theratechnologies Announces Completion of Acquisition by Future Pak
Details : Trogarzo (ibalizumab) is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors.
Product Name : Trogarzo
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 25, 2025
Lead Product(s) : Ibalizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Theratechnologies
Deal Size : Undisclosed
Deal Type : Acquisition